Parents say son with autism was nonverbal until trying an off-label drug that treats chemo side effects

Caroline Connor’s concerns about the development of her son Mason began around her first birthday, when she noticed that he did not speak or did not use words. Their pediatrician did not seem worried, but the delay in speech persisted. At 2 and a half, Mason was diagnosed with autism.

Connors have made a mission, looking for everything that would help.

“We just started looking for ourselves. And that’s when my husband Joe fell on Dr Frye in a research study he was doing,” said Caroline.

Dr. Richard Frye, a pediatric neurologist, is one of the many doctors looking for treatments that can help Autistic children. He studies Leucuvorine, an inexpensive generic drug derived from folic acid, also known as Folat or vitamin B9. Leucuvorine is currently prescribed to relieve the side effects of cancer chemotherapy. Pregnant women are prescribed by multivitamins with folic acid to prevent neuronal tube defects. The neural tube develops in the brain and spinal cord.

Leucuvorine is not a remedy for autism, but “it could really have a substantial impact on a very good percentage of autistic children,” said Frye.

“We have good preliminary evidence that leucuvorine helps,” added Frye. “But normally, the FDA would like to see at least a few major randomized clinical trials controlled by placebo. At the moment, we have only phase 2B studies, and other research is necessary to answer key questions, as how to dose it correctly, when to start and what children will benefit the most.”

The theory behind the use of autism drugs postulates that some children have a blockage in the transport of folic acid in the brain which potentially contributes to some of the neurological problems associated with the disorder. Leucuvorine bypass this blockage and can help some autistic children improve their ability to speak. Three randomized controlled trials of Leucovorine to treat autism have shown positive effects on speech.

Frye notes that there are in fact five controlled studies blind to date, all positive, although different doses and in different populations. However, he says, “the proof is not yet where it would be normally for a medication.”

Frye said he was “disappointed” that his group had not received funding from the new NIH autism data science initiative and that he was not consulted on the design of the next Leucourines trials. “It’s strange, because I have been running this work for decades,” he noted.

The science of cerebral folate deficiency

A brain deficiency in folate (CFD), or a folate deficiency in the brain, was first described by Dr. Vincent Ramaekers. Ramaekers noted that some children suffering from neurodevelopmental disorders had normal levels of folic acid in the blood, but low levels in their vertebral liquid. He then joined forces with Dr Edward Quadros, who had studied how an autoimmune disorder could lead to a blocking of folic acid transport in the brain. Ramaekers and Quadros have found that self-antibodies against the Folate Alpha (FR⍺) receiver, which transports folic acid of blood in the brain and placenta, could cause abnormal development of the fetal brain and certain disorders of the autism spectrum.

A study revealed that more than 75% of children with autistic spectrum disorder had FR⍺ autoanticorps, compared to 10 to 15% of healthy children. There is evidence that there is a family or genetic predisposition to the development of self-antibodies FR. Although the deregulation of the environment and the immune system can also play a role, there is no evidence suggesting that vaccines cause the development of self-antibodies.

The brain has a backup system for the FR⍺ known as the Reduced Folate carrier, or RFC. RFC is not as effective as the FR⍺, but it can transport leucuvorine, also known as folinic acid, in the brain. The brain enzymes convert leucuvorine into active folate.

Leucuvorine treatment increases folic levels in children with CFD. In a study led by Frye, a third of these children experienced an improvement in their discourse and other behaviors when treated with leucuvorine. Two randomized trials conducted in France and India have shown similar results. A FOLATE (Frat) self-anticorps test is available to help identify children who can best respond to leucuvorine treatment.

The Frye team has also identified new potential biomarkers, such as the soluble protein of Folate receptors, which could predict which children need higher doses.

Frye notes that there are many nuances to treat the CFD with leucuvorine, including the addition of additional treatments to optimize the mitochondrial function.

The side effects associated with leucuvorine are light. Some children experience hyperactivity during the first weeks of treatment, but which generally disappear in a month or two. A similar diagram is observed with other vitamins B.

The “little bottle of Mason’s hope”

The first words of Mason Connor came only three days after starting to take leucuvorine at the age of 3, say his parents.

Doctors can currently only prescribe the drug for autism outside MM, which means reusing a drug approved for a condition to treat another.

“We have done science, and the next step is that we want to get more funding so that we can really approve it from the FDA,” said Frye.

He welcomed the recent interest of the FDA, but warned that it was perhaps a little premature “, given the gaps in the knowledge and the need for education of doctors on how to properly prescribe leucuvorine in autism.

However, there is a big problem.

“Leucovorin is an old medication and you can get it at a very low price. So no one will earn a lot of money. So there is no reason for them to invest,” said Frye.

Compose the challenge: offer and quality vary. “Leucuvorine is a generic and different manufacturers use different additives,” said Frye. “Some formulations The autistic children do not tolerate well. We had a brand that worked beautifully, but it was exhausted at the beginning of this year. At the moment, the only reliable source is a high -quality aggravating pharmacy which knows how to do for autistic children.”

In the United States, around 20 to 30% of all prescriptions in the United States are out of AMM, according to each non-profit remedy. This is often done because there are more than 14,000 human diseases known without drugs approved by the FDA to treat them. Medicines and leucuvorine are frequently used outside the Amme because doctors think that the benefits prevail over the risks. However, there is often awareness of these treatments, so they can be unused.

Dr David Fajgenbaum said he is “literally alive today with a reused drug” after being diagnosed with a rare disease similar to cancer that has almost killed him. His research on his illness has led to a medication intended for another condition.

“It is heartbreaking to think that drugs are on the pharmacy set while someone suffers from a disease,” said Fajgenbaum.

Its non -profit organization, each remedy, uses AI to browse the medical data available on diseases and processing to discover potential correspondence. Each healing highlighted the work of Frye, Ramaekers, Quadros and others on the Leucovorine to treat autism.

“I think our system is just imperfect and there is this major gap where pharmaceutical companies are excellent for developing new drugs for new diseases, and we, as a system, are really ugly to seek new diseases for old drugs. This is why we have started each remedy – to unlock these hidden remedies,” said Fajgenbaum.

Mason is now 5 years old, and the plan is for him to start the consumer kindergarten in the fall – helped a new path with an old medication.